Skip to Main Content

Paper Details

A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Int J Cancer
0
2023
Author NameAffiliation
Bhumsuk KeamSeoul National University Hospital
  • 1 - 1

Datasets

Release 1.2